Recently, setmelanotide (Rhythm Pharmaceuticals, Boston, Massachusetts, USA) has been developed as a novel MC4R agonist for the treatment of rare genetic disorders of obesity associated with defects in the MC4 pathway. Here, MC4R is linked to obesity due to melanocortin 4 receptor deficiency.